WebJun 14, 2024 · Athira Pharma Appoints Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy. Read full article. Athira Pharma, Inc. June 14, 2024, ... WebJun 14, 2024 · Athira Pharma Appoints Rachel Lenington as Chief Technology Officer, Head of Product Development Strategy. share: Share on Facebook Tweet on Twitter Post to …
Did you know?
WebBOTHELL, Wash., June 14, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing WebJun 15, 2024 · June 15, 2024. Rachel Lenington. BOTHELL, Wash., June 14, 2024 (GLOBE NEWSWIRE) — Athira Pharma a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Rachel Lenington as Chief Technology Officer, Head of …
WebJun 15, 2024 · June 15, 2024. Rachel Lenington. BOTHELL, Wash., June 14, 2024 (GLOBE NEWSWIRE) — Athira Pharma a late clinical-stage biopharmaceutical company focused … WebJun 14, 2024 · Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, …
WebRachel Lenington. Chief Operating Officer. Rachel brings extensive strategic and operational leadership experience in drug development, commercialization and launch to Athira. … WebOct 22, 2024 · Rachel Lenington, chief technology officer, will step into Litton's former position. Athira said its lead asset, an experimental Alzheimer's drug called ATH-1017, was not the subject of Kawas ...
WebCompany profile for Athira Pharma Inc. including key executives, insider trading, ownership, ... Rachel Lenington Chief Operating Officer: 4193: Disposition at $ 2.69 per share: 11,279:
WebJun 14, 2024 · BOTHELL, Wash., June 14, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Rachel Lenington as Chief Technology Officer, Head of Product … the katarina harvesterWebRachel Lenington is Chief Operating Officer at Athira Pharma Inc. See Rachel Lenington's compensation, career history, education, & memberships. the katch lindenhurstWebNovember 10, 2024. Athira Pharma Reports Third Quarter 2024 Financial Results and Business Update. Completed enrollment of ACT-AD trial with topline data expected in the first half of 2024; LIFT-AD is actively recruiting with topline data expected by the end of 2024 – – Presented program updates and baseline data from ATH-1017’s ongoing Phase 2 and … the kate crawley storyWebMar 21, 2024 · BOTHELL, Wash., March 21, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira Pharma’s senior management team will participate in the … the katch-mcardle equationWebJun 22, 2024 · Athira Pharma announces Rachel Lenington as the Chief Technology Officer, Head of Product Development Strategy. FREMONT, CA: Athira Pharma, Inc., a late clinical-stage biopharmaceutical firm dedicated to developing small molecules to restore neuronal health and prevent neurodegeneration, has announced Rachel Lenington as the Chief … the katch venetianWebJun 14, 2024 · Ms. Lenington added, “I am delighted to join Athira’s dedicated efforts to discover and develop innovative therapies for neurodegeneration, with the ultimate goal of … the kat\u0027s meowWebApr 3, 2024 · Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. ... Rachel Lenington MBA. Chief Operating Officer. George W Bickerstaff III ... the kate chronicles